< 1 minute read
Oct. 6, 2021

BMS-986318

oral FXR agonist for NASH robust in vivo PD, phase I HV study withdrawn from prior FXR agonists ACS Med. Chem. Lett Bristol Myers Squibb, Princeton, NJ, USA

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in